Recombinant Mouse Inositol 1,4,5-trisphosphate receptor-interacting protein-like 1 (Itpripl1)

What is the molecular structure and function of Itpripl1?

Itpripl1 (Inositol 1,4,5-trisphosphate receptor-interacting protein-like 1) is a single-pass transmembrane protein that functions as a natural ligand of CD3ε. The protein has both intracellular and extracellular domains, with the extracellular domain being responsible for binding to CD3ε on T cells. This binding interaction significantly decreases calcium influx and ZAP70 phosphorylation, which are critical early events in T cell activation pathways. In the tumor microenvironment, Itpripl1 expression effectively inhibits T cell function, contributing to tumor immune evasion mechanisms. Recent research has led to Itpripl1 also being designated as CD3L1 (CD3ε ligand 1), reflecting its important role in immune regulation .

Methodological considerations: When working with recombinant Itpripl1, researchers should carefully validate protein folding and post-translational modifications, as these may affect binding affinity to CD3ε. Expression systems using mammalian cells are generally preferred over bacterial systems to ensure proper glycosylation patterns.

How is Itpripl1 expressed in normal tissues versus tumor microenvironments?

Expression correlation table across selected cancer types:

Note: TMB = Tumor Mutation Burden; MSI = Microsatellite Instability; LGG = Lower Grade Glioma; ESCA = Esophageal Carcinoma; PAAD = Pancreatic Adenocarcinoma; PRAD = Prostate Adenocarcinoma; THCA = Thyroid Carcinoma; THYM = Thymoma; BRCA = Breast Invasive Carcinoma

What experimental approaches are most effective for studying Itpripl1-CD3ε interactions?

Studying Itpripl1-CD3ε interactions requires multiple complementary approaches:

• Binding assays: Surface plasmon resonance (SPR) or biolayer interferometry (BLI) can quantify binding kinetics between recombinant Itpripl1 and CD3ε. These approaches provide critical data on binding affinity (Kd), association rate (kon), and dissociation rate (koff).

• Functional assays: Calcium flux assays using flow cytometry with calcium-sensitive dyes (e.g., Indo-1 or Fluo-4) can measure the inhibitory effect of Itpripl1 on T cell activation. Phospho-flow cytometry targeting ZAP70 phosphorylation (pY319) provides direct evidence of Itpripl1's impact on proximal T cell receptor signaling .

• Structural studies: Cryo-electron microscopy or X-ray crystallography of the Itpripl1-CD3ε complex can reveal the precise binding interface and molecular mechanisms of inhibition.

Methodological recommendation: When designing interaction studies, researchers should use both the full-length protein and the isolated extracellular domain to differentiate membrane proximity effects from direct binding interactions. Controls should include CD3ε mutants with altered binding sites to confirm specificity.

How does Itpripl1 influence immune cell infiltration and function in the tumor microenvironment?

Itpripl1 demonstrates complex relationships with various immune cell populations in the tumor microenvironment. Through comprehensive immune infiltration analysis using multiple computational approaches (CIBERSORT, MCPcounter, and ssGSEA), researchers have identified significant correlations between Itpripl1 expression and specific immune cell populations :

• Positive correlations: Itpripl1 expression positively correlates with:

  • Activated memory CD4+ T cells in pancreatic adenocarcinoma (PAAD) (Spearman r = 0.486)

  • Regulatory T cells (Tregs) in thymoma (THYM) (Spearman r = 0.530)

  • M1 macrophages in adrenocortical carcinoma (ACC) (Spearman r = 0.499)

  • T cells, CD8+ T cells, and cytotoxic lymphocytes in hepatocellular carcinoma (LIHC) and PAAD (Spearman r > 0.7)

• Negative correlations: Itpripl1 expression negatively correlates with:

  • Activated NK cells in cholangiocarcinoma (CHOL) (Spearman r = -0.451)

  • Activated dendritic cells in mesothelioma (MESO) (Spearman r = -0.455)

These correlations suggest that Itpripl1 may influence both the recruitment and functional status of various immune cell types in the tumor microenvironment, creating a complex immunoregulatory landscape .

Experimental recommendation: When studying Itpripl1's effects on immune infiltration, multiplexed immunofluorescence or single-cell RNA sequencing provides more comprehensive data than flow cytometry alone, as they can capture spatial relationships and heterogeneity in the tumor microenvironment.

What is the potential of anti-Itpripl1 antibodies as cancer immunotherapy agents?

Anti-Itpripl1 neutralizing antibodies have demonstrated promising therapeutic potential in preclinical studies. Treatment with these antibodies has been shown to:

• Restrain tumor growth across various solid tumor types in mouse models

• Promote T cell infiltration into the tumor microenvironment

• Show notable therapeutic efficacy against naturally occurring tumors in canine models in veterinary clinical settings

The therapeutic mechanism appears to involve blocking Itpripl1's inhibitory effect on T cell activation during the critical "signal one" phase of T cell priming. This represents a distinct mechanism from established immune checkpoint inhibitors that target PD-1/PD-L1 or CTLA-4 pathways .

Methodological considerations: When developing and testing anti-Itpripl1 antibodies:

• Verify antibody specificity through both binding and functional assays

• Test combinations with established checkpoint inhibitors to assess potential synergistic effects

• Include PD-L1-low tumor models to better understand the therapeutic niche

How can researchers effectively measure the functional consequences of Itpripl1 inhibition?

Measuring the functional impact of Itpripl1 inhibition requires multi-parameter analysis:

• T cell activation markers: Flow cytometry assessment of CD69, CD25, and CD44 upregulation provides early indicators of enhanced T cell activation following Itpripl1 blockade.

• Cytokine production: Multiplex cytokine assays (e.g., Luminex) to quantify IFN-γ, TNF-α, and IL-2 production by T cells provides functional readouts of enhanced T cell activity.

• Tumor response metrics: In vivo studies should measure:

  • Tumor volume and growth kinetics

  • Immune cell infiltration (quantity and quality)

  • Spatial relationships between T cells and tumor cells using multiplexed imaging

  • Transcriptional changes in both immune and tumor compartments

Analytical recommendation: Single-cell approaches (scRNA-seq, CyTOF) provide greater resolution of cell population heterogeneity and can identify specific T cell subsets most affected by Itpripl1 inhibition.

What are the optimal expression systems for producing functionally active recombinant mouse Itpripl1?

The choice of expression system significantly impacts the functional properties of recombinant Itpripl1:

• Mammalian expression systems: HEK293 or CHO cells are preferred for producing properly folded and glycosylated Itpripl1. These systems better recapitulate the post-translational modifications present in native Itpripl1, which are critical for CD3ε binding.

• Purification strategies: A two-step purification approach combining affinity chromatography (using a His-tag or Fc-fusion) followed by size exclusion chromatography is recommended to ensure high purity while preserving protein conformation.

• Quality control measures: Functional validation through CD3ε binding assays and T cell inhibition assays is essential, as protein activity cannot be assumed solely from purity or yield metrics.

Technical recommendation: Expression constructs should be designed with removable tags to allow comparative studies of tagged versus untagged protein, ensuring that the tag does not interfere with protein function.

How can researchers develop reliable mouse models to study Itpripl1 biology in cancer?

Developing appropriate mouse models for Itpripl1 research requires careful consideration:

• Genetic models:

  • Conditional Itpripl1 knockout models using Cre-loxP systems allow tissue-specific studies

  • CRISPR-engineered point mutations can recapitulate specific functional domains

• Tumor models:

  • Syngeneic models with varied Itpripl1 expression levels are valuable for studying immune effects

  • Orthotopic models better recapitulate the physiological tumor microenvironment than subcutaneous models

  • Patient-derived xenografts in immunodeficient mice reconstituted with human immune components can provide translational insights

• Validation approaches:

  • Immunohistochemistry to confirm Itpripl1 expression patterns

  • Flow cytometry to assess immune infiltration dynamics

  • RNA-seq to identify transcriptional changes in both tumor and immune populations

Design recommendation: Include multiple tumor models representing both PD-L1-high and PD-L1-low phenotypes to understand the relationship between different immune checkpoint mechanisms .

What are the potential experimental pitfalls when studying Itpripl1 and how can they be addressed?

Common challenges in Itpripl1 research include:

• Antibody specificity issues: Commercial antibodies may cross-react with related proteins. Validation recommendations:

  • Use knockout controls to confirm specificity

  • Employ multiple antibodies targeting different epitopes

  • Verify with orthogonal methods (RNA expression, mass spectrometry)

• Expression level variability: Itpripl1 expression can vary significantly between models and conditions:

  • Quantify expression using qPCR and Western blot before functional studies

  • Consider inducible expression systems for controlled experiments

  • Account for potential alternative splicing when designing detection methods

• Functional redundancy: Other immune regulatory pathways may compensate for Itpripl1 inhibition:

  • Design combinatorial blocking experiments

  • Perform comprehensive immune profiling when assessing intervention effects

  • Monitor multiple T cell activation parameters simultaneously

Analytical consideration: When analyzing correlations between Itpripl1 expression and immune cell infiltration, use multiple computational methods (e.g., CIBERSORT, MCPcounter, ssGSEA) to improve robustness of findings, as each algorithm has different assumptions and limitations .

How does mouse Itpripl1 compare to human ITPRIPL1 in structure and function?

Understanding the comparative biology between mouse Itpripl1 and human ITPRIPL1 is critical for translational research:

• Sequence homology: While the proteins share significant sequence homology, key differences exist in the extracellular domain that may affect CD3ε binding properties.

• Functional conservation: Both mouse and human proteins inhibit T cell activation through CD3ε binding, but binding affinity and downstream signaling effects may differ quantitatively.

• Expression patterns: Cross-species comparison of expression patterns across tissues and tumor types reveals both similarities and differences that must be considered when extrapolating from mouse models.

Methodological approach: When validating mouse findings for human relevance:

• Perform parallel binding and functional assays with both species' proteins

• Use humanized mouse models where appropriate

• Validate key findings in human samples through ex vivo functional studies

What is the relationship between Itpripl1 and other immune checkpoint pathways?

Itpripl1 functions within a complex network of immune regulatory mechanisms:

• Relationship with PD-1/PD-L1 pathway: Itpripl1 is commonly observed in tumors with low PD-L1 expression, suggesting a potentially complementary role in immune evasion. This pattern indicates that Itpripl1 may be particularly important in tumors that do not heavily rely on the PD-1/PD-L1 axis .

• Integration with other immune checkpoints: Correlation analysis shows significant associations between Itpripl1 expression and multiple immune checkpoint genes across several cancer types, including ACC, BRCA, KICH, LIHC, LUAD, PAAD, PRAD, THCA, and DLBC .

• Unique mechanism: Unlike many checkpoint receptors that affect T cell function through co-inhibitory signaling, Itpripl1 directly interferes with TCR signaling at the "signal one" phase through CD3ε binding .

Experimental design recommendation: When studying combination therapies, factorial experimental designs with single and combined blockade of Itpripl1 and established checkpoints (PD-1, CTLA-4) provide more comprehensive data than sequential testing approaches.

What are the promising areas for further investigation of Itpripl1 biology?

Several high-priority research directions emerge from current knowledge:

• Structural biology: Determining the crystal structure of the Itpripl1-CD3ε complex would provide critical insights for rational drug design and understanding molecular mechanisms.

• Regulatory mechanisms: Investigating the transcriptional and post-transcriptional regulation of Itpripl1 expression in different contexts could reveal strategies to modulate its expression therapeutically.

• Biomarker development: Further investigation of Itpripl1 as a predictive biomarker for immunotherapy response, particularly in tumors with low PD-L1 expression, represents an important clinical research opportunity .

• Alternative functions: Beyond CD3ε binding, exploration of potential additional binding partners and signaling roles for Itpripl1 may reveal unexpected biology.

Methodological consideration: Systems biology approaches integrating proteomics, transcriptomics, and functional genomics will likely be required to fully elucidate the complex role of Itpripl1 in immune regulation.

How might Itpripl1 research inform combination immunotherapy strategies?

The emerging understanding of Itpripl1 suggests several strategic approaches to combination therapy:

• Dual checkpoint blockade: Combining anti-Itpripl1 antibodies with established checkpoint inhibitors may overcome resistance mechanisms, particularly in tumors with low PD-L1 expression .

• Sequential therapy approaches: Given its role in early T cell activation, Itpripl1 blockade may be particularly effective as an initial treatment to enhance T cell priming, followed by other agents targeting later stages of T cell function.

• Biomarker-guided combinations: Tumor Itpripl1 expression levels could potentially guide the choice of immunotherapy combinations, allowing for more personalized treatment approaches.

Research recommendation: Preclinical studies should incorporate comprehensive immune monitoring to understand the mechanistic basis of combination effects, rather than focusing solely on tumor growth outcomes.